Related Experiment Video

Updated: Jun 4, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.0K

Long non-coding RNA MSC-AS1 confers imatinib resistance of gastrointestinal stromal tumor cells by activating FNDC1

Lin Chen1, Yongjian Gao1, Huaixi Yang1

  • 1Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital of Jilin University, No. 126 Sendai Street, Nanguan District, Changchun, 130031, China.

Human Cell
|January 3, 2025
PubMed

Insights

This study identifies MSC-AS1 as a key long non-coding RNA driving imatinib resistance in gastrointestinal stromal tumors (GIST). Suppressing MSC-AS1 may offer a new strategy to overcome drug resistance in GIST patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Imatinib resistance poses a significant challenge in treating gastrointestinal stromal tumors (GIST).
  • Long non-coding RNAs (LncRNAs) are emerging as critical regulators in chemotherapy resistance.
  • Understanding the molecular mechanisms of imatinib resistance in GIST is crucial for developing effective therapies.

Purpose of the Study:

  • To identify key long non-coding RNAs (lncRNAs) involved in imatinib resistance in GIST.
  • To elucidate the functional role and underlying mechanism of MSC-AS1 in GIST imatinib resistance.

Main Methods:

  • Analysis of lncRNA expression in imatinib-resistant GIST tissues and cells.
  • In vitro cellular experiments assessing cell survival, colony formation, migration, and invasion upon MSC-AS1 modulation.
  • Investigation of the molecular mechanism involving miR-200b-3p, FNDC1, Anillin, and the PI3K-AKT signaling pathway.
  • In vivo validation of MSC-AS1's role in imatinib resistance.

Main Results:

  • MSC-AS1 was found to be significantly upregulated in imatinib-resistant GIST.
  • Overexpression of MSC-AS1 reduced GIST cell sensitivity to imatinib, enhancing cell survival, proliferation, migration, and invasion.
  • Suppression of MSC-AS1 reversed imatinib resistance in GIST cells.
  • MSC-AS1 acts by sponging miR-200b-3p, leading to upregulation of FNDC1 and Anillin, and activation of the PI3K-AKT pathway.

Conclusions:

  • MSC-AS1 plays a critical role in mediating imatinib resistance in GIST.
  • The MSC-AS1/miR-200b-3p/FNDC1/Anillin axis and PI3K-AKT pathway activation are key mechanisms driving this resistance.
  • Targeting MSC-AS1 presents a potential therapeutic strategy to overcome imatinib resistance in GIST.
Keywords:
Gastrointestinal stromal tumorsImatinib resistanceLong noncoding RNA

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K